Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Crinetics Pharmaceuticals, Inc. - Common Stock (NQ:CRNX)

83.94 +0.09 (+0.11%)
Streaming Delayed Price Updated: 11:33 AM EDT, Jul 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Crinetics Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching ↗
The biotech's diversification efforts continue. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals ↗
Vertex's $10 billion acquisition may have spooked investors, given how rich it appeared to be. 
Via The Motley Fool
News headline image
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy? ↗
Vertex Pharmaceuticals recently announced its largest-ever acquisition. 
Via The Motley Fool
Crinetics Pharmaceuticals (NASDAQ:CRNX) Beats Q1 Expectations on Strong PALSONIFY Launch, Stock Slips After Hours ↗
Via Chartmill
Crinetics Pharmaceuticals (NASDAQ:CRNX) Beats Q4 Revenue Estimates on First Product Sales ↗
Via Chartmill
News headline image
Is This Biotech Stock a Buy Near Its 52-Week High? ↗
It's been a volatile year for the company, but don't let that scare you away. 
Via The Motley Fool
News headline image
Why This Pharmaceutical Stock Jumped Close to 100% This Week ↗
It is getting acquired by a larger firm in the sector. 
Via The Motley Fool
Topics Bonds
News headline image
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy? ↗
Additional blockbuster drugs may be on the horizon. 
Via The Motley Fool
Topics Intellectual Property
On Thursday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
News headline image
Here's How Much $1000 Invested In Crinetics Pharmaceuticals 5 Years Ago Would Be Worth Today ↗
Crinetics Pharmaceuticals (NASDAQ:CRNX) has outperformed the market over the past 5 years by 21.74% on an annualized basis producing an average annual return of 33.07%. Currently, Crinetics... 
Via Benzinga
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
News headline image
Vertex’s Crinetics Deal Balances Growth with Integration Risk ↗
Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis... 
Via MarketBeat
News headline image
Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It. ↗
This buy gives Vertex both a recently-commercialized drug, and a very strong lead candidate. 
Via The Motley Fool
News headline image
Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know. ↗
The drugmaker is paying up for a new growth engine. Is the price disciplined? 
Via The Motley Fool
Topics Intellectual Property
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
Most active stocks in Tuesday's session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tuesday's regular session. The company's market cap stands at $4.4 billion. Tvardi Therapeutics... 
Via Benzinga
Top stock movements in today's session. ↗
Via Chartmill
The market is filled with gapping stocks in Tuesday's session. ↗
Via Chartmill
Discover the top movers in Tuesday's pre-market session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) stock increased by 98.9% to $83.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.4 billion. Bluejay... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers Vicore Pharma Holding (NASDAQ:VCRE) stock rose 149.8% to $42.47 during Monday's after-market session. Crinetics Pharmaceuticals (NASDAQ:CRNX) stock moved upwards by 99.85% to $84.0. The... 
Via Benzinga
Monday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗
Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Crinetics (CRNX) Q1 2026 Earnings Transcript ↗
Crinetics (CRNX) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More ↗
This biotech specializing in endocrine therapies reported a notable insider sale as it advances clinical-stage drug candidates. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough ↗
This biotech specializes in therapies for neurological disorders, advancing a diverse pipeline through late-stage trials and collaborations. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know ↗
This energy storage firm develops battery solutions for utility and commercial clients, targeting grid-scale renewable energy markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings ↗
Praxis Precision Medicines focuses on clinical-stage therapies for central nervous system disorders, targeting unmet needs in neurology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Crinetics (CRNX) Q4 2025 Earnings Call Transcript ↗
Crinetics (CRNX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.